Book Description:
Alzheimer¡¯s disease (AD), the most common form of neurodegenerative disorder in the elderly, is characterized pathologically by extracellular amyloid plaques and intracellular neurofibrillary tangles, pathophysiologically by synaptic dysfunction, and clinically by a progressive decline in cognition. Currently, AD has no cure and its prevalence is predicted to triple by 2050 with the rapid increase in the aging population, unless more effective prevention/treatments are developed. Since the publication of the third book volume, the rapid progress in the research fields of AD and dementia continues through the intensive efforts of research scientists worldwide. This fourth book volume contains 12 chapters, bringing together a presentation of scientific frontiers in current AD/dementia research. The topics include emotional memory in AD, amyloid-B clearance, synaptic transmission-mediated regulation of amyloid-B dynamics, anti-AD immunotherapy, clinical trials of AD therapeutics using AD transgenic mouse models, roles of apolipoprotein E, chronic inflammation, cathepsins, and gelsolin in AD pathogenesis and as anti-AD therapeutic targets/agents, declarative memory impairment and hippocampal atrophy in Parkinson¡¯s disease, fronto-temporal dementia, and cognitive impairment in schizophrenia. These chapters cover current advances in our understanding of the pathogenic mechanisms underlying AD and dementia, in the diagnosis of early AD and dementia, and in the development of therapeutic agents that target memory-relevant AD pathogenesis. The book will be highly valuable to students and scientists worldwide who are interested in the scientific research progress in AD and memory disorders.

Table of Contents:
Preface

1. Emotional Memory in Alzheimer¡¯s Disease
(Jill D. Waring and Elizabeth A. Kensinger, Department of Psychology, Boston College, Chestnut Hill, MA USA) pp.9-36

2. Mechanisms of Amyloid-B Clearance in Alzeheimer's Disease
(Joseph El Khoury, Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology and Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, and Suzanne E. Hickman, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA)pp.37-66

3. Synaptic transmission regulates amyloid-¦Â dynamics
(John R. Cirrito, Department of Neurology, Washington University School of Medicine, St. Louis, MO)pp.67-84

4. Anti-AB Antibodies For the Treatment of Alzheimer's Disease
(Bin Liu*, Hongjun Fu*, Jeffrey L. Frost, and Cynthia A. Lemere Center for Neurologic Disease, Brigham & Women¡¯s Hospital and Harvard Medical School, Boston, MA)pp.85-112

5. The Failure of the APP Transgenic Mouse Models to Predict Efficacy of Agents in Five Clinical Trials of Alzheimer¡¯s Disease Suggests That There is a Need for a New Paradigm for Drug Development.
(Jordan L. Holtzman, University of Minnesota, Minneapolis, MN)pp.113-144

6. Apolipoprotein E and Alzheimer¡¯s Disease: An Update on Allele-Specific Effects of Disease Etiology
(Ann M. Saunders, Genetics Research GlaxoSmithKline R&D
Research Triangle Park, NC)pp.145-160

7. Chronic Inflammation and Alzheimer¡¯s Disease
(Douglas G. Walker, Jason Yuan and Lih-Fen Lue, Sun Health Research Institute, Sun City, AZ)pp.161-184

8. Cathepsins in Alzheimer¡¯s disease and dementia: Cathepsin inhibitors as potential anti-dementic therapeutics
(Azizul Haque, Naren L. Banik1,and Swapan K. Ray, Medical University of South Carolina, Charleston, SC and University of South Carolina School of Medicine, Columbia, SC)pp.185-198

9. Role of gelsolin in Alzheimer¡¯s disease
(Lina Ji, Abha Chauhan, Ved Chauhan, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY)pp.199-218

10. Declarative memory impairment and hippocampal atrophy in Parkinson¡¯s disease
(Carme Junque, Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain)pp.219-242

11. Fronto-temporal dementia
(Alfredo Postiglione, Graziella Milan and Sabina Pappat¨¤, University of Naples, Naples, Italy and Institute of Biostructures & Bioimaging, CNR, Naples, Italy)pp.243-262

12. Cognitive impairment in schizophrenia
(Verity C Leeson and Eileen M Joyce, UCL Institute of Neurology, Queen Square, London) pp.263-280

Index pp.281-306